Vascular Phenotypes in a Geriatric Populatio
- Conditions
- <p>Memory complaints, microvascular damage, macrovascular damage</p>
- Registration Number
- NL-OMON29291
- Lead Sponsor
- Amsterdam University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
Age of 65 years or older
-Signed informed consent for the general protocol (METc 2017.148)
Exclusion Criteria
-Insufficient proficiency of the Dutch language.
- Severe cognitive impairment: MMSE score < 16.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters are different vascular phenotypes, based on measurements of macro- and microvascular function.</p>
- Secondary Outcome Measures
Name Time Method <p>Secondary study parameters are cognitive functioning, as assessed by neuropsychological assessment, physical performance (handgrip strength, gait speed and Short Physical Performance Battery) and functional outcomes: activities of daily living (ADL) and instrumental ADL (iADL) dependence levels, quality of life, (serious) adverse events and mortality.</p>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link microvascular damage to memory complaints in geriatric vascular phenotypes?
How do plasma biomarkers for cerebral microvascular injury correlate with cognitive decline in NL-OMON29291?
What comparative effectiveness data exists for statins vs. antiplatelet agents in geriatric macrovascular disease management?
Which geriatric subpopulations show highest risk for adverse events from vascular aging in observational studies?
How does endothelial dysfunction in NL-OMON29291 relate to novel antihypertensive drug targets for elderly patients?